Case-Based Roundtable Meetings Spotlight: March 2, 2023

During a Targeted Oncology™ Case-Based Roundtable™ event, Hetty E. Carraway, MD, MBA, discussed with participants diagnosing and treating patients with BPDCN, as well as the remaining challenges in this space.

During a Targeted Oncology™ Case-Based Roundtable™ event, Amrita Krishnan, MD, discussed with participants their choice of therapy for a patient with multiple myeloma who relapsed after receiving bortezomib, lenalidomide, and dexamethasone followed by autologous stem cell transplant and 2 years of lenalidomide maintenance.

During a Targeted Oncology™ Case-Based Roundtable™ event, Anna C. Pavlick, DO, MSc, MBA, BSN, discussed first-line therapy for a patient with metastatic melanoma.

During a Targeted Oncology™ Case-Based Roundtable™ event, Bruce D. Cheson, MD, discussed adverse event management and dosing strategies for patients receiving tafasitamab and lenalidomide for diffuse large B-cell lymphoma.

During a Targeted Oncology™ Case-Based Roundtable™ event, Stephen Oh, MD, discussed treatment options for steroid-refractory high-risk primary myelofibrosis based on the patient's platelet count.

Gary J. Schiller, MD, discusses the treatment for blastic plasmacytoid dendritic cell neoplasm and what clinicians need to look out for when evaluating these rare occurrences.

During a Targeted Oncology™ Case-Based Roundtable™ event, Hatim Husain, MD, discussed data on targeted adjuvant therapy for non–small cell lung cancer.

In separate live, virtual events, Ulka N. Vaishampayan, MBBS, and David A. Braun, MD, PhD, discussed options for a patient with favorable-risk clear cell renal cell carcinoma.

During a Targeted Oncology™ Case-Based Roundtable™ event, Jaffer A. Ajani, MD, discussed the trials investigating the use of immune checkpoint inhibitors in patients with upper gastrointestinal cancers.

During a Targeted Oncology™ Case-Based Roundtable™ event, Daniel Geynisman, MD, discussed with participants the choice of hormonal therapy for metastatic prostate cancer.

During a Targeted Oncology™ Case-Based Roundtable™ event, Richard Finn, MD, discussed how treatment options for patients with hepatocellular carcinoma have advanced in recent years.

During a Targeted Oncology™ Case-Based Roundtable™ event, Bhavana Pothuri, MD, MS, discussed with participants their experiences managing adverse events of immunotherapy for advanced endometrial cancer.

During a Targeted Oncology™ Case-Based Roundtable™ event, Timothy F. Burns, MD, PhD, discussed the trials supporting the use of mobocertinib and amivantamab for patients with non–small cell lung cancer and an EGFR exon 20 insertion.